San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
NEW YORK, June 08, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the U.S. District Court for the Southern District of New York on behalf of investors who purchased Neurotrope, Inc. ("Neurotrope") (NASDAQ:NTRP) securities between January 7, 2016, and April 28, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/neurotrope-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the class period, Neurotrope issued materially false and misleading statements and/or failed to disclose material information concerning the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, Neurotrope issued a press release announcing “positive top-line results” of the pivotal Phase 2b trials of Bryostatin-1, noting “improvement in patients with moderate to severe Alzheimer’s disease.” However, the underlying trial data contradicts these representations, as the top-line data relating to the 20 microgram dose of Bryostatin-1 failed to produce results that were statistically significant. In addition, Neurotrope failed to disclose statements regarding the efficacy of the 40 microgram dose with regard to its primary and secondary endpoints. Upon this news, shares of Neurotrope fell from a close of $18.81 on April 28, 2017, to a close of $6.97 per share on May 1, 2017.
If you suffered a loss in Neurotrope you have until July 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/neurotrope-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
